Personalized management of patients with solid cancers: Moving from patient characteristics to tumor biology

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 297-304

  Awada, Ahmad ^a   Vandone, Anna M ^a   Aftimos, Philippe ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

gene profiling; molecular biology advances; personalized cancer management; solid cancers; targeted therapies

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DENOSUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; K RAS PROTEIN; LAPATINIB; NERATINIB; OLAPARIB; PANITUMUMAB; PERTUZUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; VEMURAFENIB; VISMODEGIB;

BASAL CELL CARCINOMA; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GIANT CELL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PATHOLOGY, MOLECULAR;

EID: 84859839784     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283521349     Document Type: Review

References (70)

1. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33:466-477. (Pubitemid 34747865)
2. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215:68-77.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580. (Pubitemid 28067289)
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056. (Pubitemid 32267975)
5. Dematteo RP, Ballman KV, Antonescu CR, et al.; and the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind placebo-controlled study. Lancet 2009; 373:1097-1104.
6. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastroinstestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349. (Pubitemid 46621810)
7. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710. (Pubitemid 36159485)
8. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134. (Pubitemid 39296599)
9. Ikezoe T, Yang Y, Nishioka C, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006; 97:945-951. (Pubitemid 44151278)
10. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
11. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874. (Pubitemid 32878711)
12. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560-569. (Pubitemid 44200649)
13. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analyses of gene expression profiles in breast cancer: toward a unified under standing of breast cancersubtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65.
14. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239-1246. (Pubitemid 46640570)
15. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.
16. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
17. Zamble DB, Mu D, Reardon JT, et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996; 35:10004-10013. (Pubitemid 26269915)
18. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-linkinduced double-strand breaks. Mol Cell Biol 2004; 24:5776-5787. (Pubitemid 38787963)
19. Sargent RG, Meservy JL, Perkins BD, et al. Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 2000; 28:3771-3778.
20. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991. (Pubitemid 44343542)
21. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800.
22. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expresssion signature as a predictor of servival in breast cancer. N Engl J Med 2002; 347:1999-2009. (Pubitemid 35461656)
23. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26:729-735. (Pubitemid 351264385)
24. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826. (Pubitemid 40051905)
25. Paik S, Tang G, Shak S, et al.Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-3734. (Pubitemid 46622311)
26. Albain KS, Barlow WE, Shak S, et al.; and the Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55-65.
27. Harris L, Fritsche H, Mennel R, et al.; and the American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-5312. (Pubitemid 350232263)
28. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26:721-728. (Pubitemid 351264384)
29. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077-3080.
30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; and the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672. (Pubitemid 41464705)
32. & Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
33. Chapman PB, Hauschild A, Robert C, et al.; and the BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; and the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
35. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol 2004; 22:1103-1109. (Pubitemid 41095044)
36. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21:2237-2246. (Pubitemid 46621858)
37. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158. (Pubitemid 37432975)
38. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. (Pubitemid 38637993)
39. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
40. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22. (Pubitemid 37328883)
41. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308. (Pubitemid 46480970)
42. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-515. (Pubitemid 351325672)
43. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2:e17.
44. Van Cutsem E, Kö hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
45. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panutumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634.
46. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
47. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23:8597-8605. (Pubitemid 46211501)
48. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205.
49. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25:3808-3815. (Pubitemid 47477254)
50. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381-5387. (Pubitemid 46623169)
51. Slamon D, Eiermann W, Robert N, et al.; and the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273-1283
52. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
53. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005; 23:4287-4297. (Pubitemid 46207003)
54. Paik S, Liu ET. HER2 as a predictor of therapeutic response in breast cancer. Breast Dis 2000; 11:91-102. (Pubitemid 30599165)
55. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004; 86:197-206. (Pubitemid 39070962)
56. Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracyclinebased chemotherapy. J Clin Oncol 2011; 29:859-867.
57. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to prediciting resistance to anthracyclines. J Clin Oncol 2011; 29:1578-1586.
58. Di Leo A, Desmedt C, Bartlett JM, et al.; and the HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracyclinecontaining chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011; 12:1134-1142.
59. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345. (Pubitemid 38944402)
60. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced nonsmall-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12:30-37.
61. Gough AC, Smith CA, Howell SM, et al. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 1993; 15:430-432. (Pubitemid 23099816)
62. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17:93-101.
63. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use,and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-39.
64. Borges S, Desta Z, Li L, et al. Quantative effect of CYP2D6 genotypes and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80:61-74. (Pubitemid 43946844)
65. Dezentjé VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28:2423-2429.
66. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexer genotyping of nonsmall-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616-2624.
67. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011; 29:1236-1238.
68. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 2011; doi:10.1158/2159-8274.
69. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86:97-100.
70. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3:111ra121.